Nonfusion Alternative To Artificial Discs Acquired By Abbott/Spinal Concepts
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs will launch a clinical trial early next year supporting a PMA submission for Spine Next's Wallis nonfusion spine stabilization device, having acquired the French manufacturer for $60 mil. and potential milestone payments
You may also be interested in...
Zimmer Rounds Out Spinal Offerings With Abbott Spine Acquisition
Zimmer's $360 million acquisition of Abbott's spinal surgery business will add pedicle screws and an interspinous stabilizer system to help round out Zimmer's own spinal offerings and create "critical mass" in the spinal business, the company says
Zimmer Rounds Out Spinal Offerings With Abbott Spine Acquisition
Zimmer's $360 million acquisition of Abbott's spinal surgery business will add pedicle screws and an interspinous stabilizer system to help round out Zimmer's own spinal offerings and create "critical mass" in the spinal business, the company says
Abbott’s Wallis trial
First subject implanted in the U.S. with the firm's Wallis dynamic stabilization spinal implant to treat degenerative disc disease as part of a 340-patient, 20-center clinical trial to support PMA approval. Unlike total disc replacement, such as Johnson & Johnson's Charité, the device does not require an abdominal insertion and does not replace the disc but instead re-routes spinal load through the use of spacers. Abbott acquired Wallis developer Spine Next for $60 mil. in 2004 (1"The Gray Sheet" Nov. 1, 2004, p. 5)...